The cessation of @entity739 and the disappearance of @entity739 in @entity25 are the criteria for successful treatment in @entity739 . In a prospective study at the @entity1 's University Hospital, 28 @entity1 with @entity739 (17 symptomatic, 7 cryptogenic, 4 idiopathic) were treated with @entity5305 monotherapy for at least 2 weeks. Seven @entity1 received @entity5305 150 mg/kg/day, and 21 @entity1 received 65-75 mg/kg/day. @entity1 were classified as responders, when @entity739 and @entity739 in @entity25 disappeared within 2 weeks. After 2 weeks, 18 @entity1 were @entity410 -free, 14 without @entity739 . Fourteen @entity1 were responders (8 symptomatic, 3 cryptogenic, 3 idiopathic), and 14 non-responders. The follow-up encompassed 6 months to 5.3 years (mean 20.3 months). In the responder group, 12/14 @entity1 (6 symptomatic, 3 cryptogenic and 3 idopathic) remained @entity410 -free, no relapse of @entity739 occurred. In the non-responder group, ACTH was efficient in 11, @entity1092 in 2 @entity1 and @entity2053 in 1 @entity1 . Relapse occurred in 4 @entity1 after discontinuation of ACTH. At last visit EEG was normal in 8/14 responders and 1/14 non-responders. The efficacy of @entity5305 monotherapy was comparable to ACTH and occurred within 2 weeks.

@entity5305 as a first-line drug in XXXX : clinical and electroencephalographic outcome.

@entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients', 'Children', 'child'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure'] @entity5305 :: ('MESH:D020888', 'Chemical') :: ['vigabatrin'] @entity1092 :: ('MESH:D014635', 'Chemical') :: ['valproic acid'] @entity739 :: ('MESH:D013036', 'Disease') :: ['hypsarrhythmia', 'infantile spasms', 'West syndrome'] @entity2053 :: ('MESH:D002998', 'Chemical') :: ['clonazepam'] @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep EEG']
@entity739 :: (MESH:D013036,Disease) :: ['West syndrome']
